Theralase Technologies (TSE:TLT) has released an update.
Theralase Technologies Inc., a clinical stage pharmaceutical company, has announced their intention to extend the expiry date of 10 million share purchase warrants from September 2024 to September 2027. The warrants, exercisable at $0.35 per share, were initially issued during a private placement in September 2022, and the extension is pending final acceptance by the TSX Venture Exchange.
For further insights into TSE:TLT stock, check out TipRanks’ Stock Analysis page.
